ClinicalTrials.gg
RecruitingNCT06807437Updated Nov 6, 2026

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

A Phase 3 interventional study of Biospecimen Collection and Distal Pancreatectomy in Pancreatic Carcinoma and Pancreatic Neoplasm, sponsored by SWOG Cancer Research Network. Recruiting at 118 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by SWOG Cancer Research Network · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Nov 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
274
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Planned enrollment
135th of 1,573
274 · median 37
Started
2025
with 67 others
Phase 3
80 of 1,850
14 open now
Primary completion
2029-04
later than 389 of 468 live
Registered
1,714th of 1,850
by date

Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 135th largest by planned enrollment of the 1,573 interventional ones that give a count, is one of 68 that started in 2025, is one of 80 in phase 3, reaches primary completion later than 389 of the 468 other live ones, and was the 1,714th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

292 more — sign in →

All 297 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,850 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.

Read the detailed description

PRIMARY OBJECTIVE:

I. To compare the incidence of postoperative pancreatic fistula (POPF) occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo prior to undergoing distal pancreatectomy for biopsy-proven or suspected neoplasm.

SECONDARY OBJECTIVES:

I. To compare the incidence of International Study Group of Pancreatic Surgery (ISGPS)-defined biochemical leak occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo in the subset of participants with a drain placed.

II. To compare the number of postoperative days in the hospital within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo.

III. To compare change from baseline in cancer-specific quality of life at 14 and 60 days after surgery, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30-(C30), in participants randomized to receive preoperative lanreotide versus placebo.

ADDITIONAL OBJECTIVES:

I. To compare change from baseline in pancreatic cancer-specific quality of life and overall health-related quality of life at 14 and 60 days after surgery, as measured by the EORTC QLQ- Pancreatic Cancer 26 (PAN26) and European Quality of Life Five Dimension Five Level (EQ-5D-5L), in participants randomized to receive preoperative lanreotide versus placebo.

II. To compare the proportions of participants with common postoperative sequelae associated with POPF, including ISGPS delayed gastric emptying and ISGPS post pancreatectomy hemorrhage (grades B/C) occurring within 60 days after surgery, in participants randomized to receive preoperative lanreotide versus placebo.

III. To compare time from surgery to initiation of adjuvant chemotherapy among participants with pancreatic ductal adenocarcinoma and planned adjuvant chemotherapy randomized to receive preoperative lanreotide versus placebo.

BANKING OBJECTIVE:

I. To bank blood, pancreas fluid, and tissue specimens for future correlative studies.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive lanreotide subcutaneously (SC) over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

ARM II: Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

After completion of study treatment, patients are followed up at 4, 8 and 12 months after surgery.

03

Conditions studied

  • Pancreatic Carcinoma
  • Pancreatic Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential
  • Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration/randomization date
  • Participants must not have a known history of a prior diagnosis of malabsorption syndrome
  • Participants must not have been treated with any somatostatin analogue within 180 days prior to registration/randomization
  • Participants must not have been treated with radiation therapy for their pancreas at any time prior to registration/randomization
  • Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration/randomization
  • Participants must be ≥ 18 years old
  • Participants must have a complete documented medical history and physical exam within 28 days prior to registration/randomization
  • Participants must have a creatinine ≤ the institutional (IULN) OR a measured OR calculated ≥ 50 mL/min using the following Cockcroft -Gault formula within 60 days prior to registration/randomization
  • Participants must complete a pre-registration screening to identify any of the medications below, allowing the study team and treating physician to develop a monitoring plan as needed. Participants taking medications with known interactions with lanreotide may remain eligible if appropriate monitoring and management are in place. These medications include:

    • Diabetes medications (insulin or oral hypoglycemics): Blood sugar will be monitored, and medication dose adjustments made as needed
    • Cyclosporine: Dosage adjustments may be required to maintain therapeutic levels
    • Bromocriptine: Dose adjustments may be considered to account for absorption changes
    • Heart medications (e.g., beta blockers): Heart rate will be monitored, and medication doses adjusted if necessary
    • -metabolized medications: Dose adjustments may be considered to avoid increased exposure
  • In the opinion of the treating surgeon, based on preoperative data, the participant must not require a modified Appleby-type procedure (distal pancreatectomy with celiac axis resection) or multivisceral resection (e.g., stomach, colon, etc.) at the time of distal pancreatectomy

    • NOTE: planned removal of the gallbladder or spleen at the time of distal pancreatectomy is not considered multivisceral resection and is permissible
  • In the opinion of the treating surgeon, based on preoperative data, the participant must not require a tumor enucleation
  • Participants must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either [AST] > 190 U/L or alanine aminotransferase [ALT] > 320 U/L) within 60 days prior to registration/randomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable
  • Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped)
  • Individuals who are of must have agreed to use an effective method during the whole period of the study and for three months after the study drug administration, with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
  • Participants must be offered the opportunity to participate in specimen banking
  • Participants who can complete EORTC QLQ-C30, EORTC QLQ-PAN26, and EQ-5D-5L forms in English or Spanish, must be offered the opportunity to participate in the quality-of-life study
  • NOTE: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
  • Participants must be informed of the nature of this study and must sign and give in accordance with institutional and federal guidelines
  • For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
274 participants (estimated)

Study arms

  • Experimental
    Arm I (lanreotide, distal pancreatectomy)

    Patients receive lanreotide SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

    Procedure: Biospecimen Collection · Procedure: Distal Pancreatectomy · Drug: Lanreotide · Other: Questionnaire Administration

  • Placebo comparator
    Arm II (saline placebo, distal pancreatectomy)

    Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

    Procedure: Biospecimen Collection · Procedure: Distal Pancreatectomy · Other: Questionnaire Administration · Other: Saline

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample and pancreas fluid collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureDistal Pancreatectomy

    Undergo distal pancreatectomy

  • Given SC

    Also known as: Angiopeptin, BIM-23014, DC 13116, Dermopeptin, Ipstyl, Somatulina, Somatuline

  • OtherQuestionnaire Administration

    Ancillary studies

  • OtherSaline

    Given SC

    Also known as: ISOTONIC SODIUM CHLORIDE SOLUTION, Normal Saline, Sodium Chloride 0.9%

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative pancreatic fistula (POPF)

    POPF will be assessed using the 2016 International Study Group for Pancreas Surgery (ISGPS). Incidence rates of POPF in each treatment arm will be described, and treatment arm differences assessed via logistic regression model with adjustment for stratification factor.

    Time frame: Up to 60 days after distal pancreatectomy

Secondary outcomes

  1. Incidence of biochemical leak (BL)

    BL will be defined by the ISGPS as a peritoneal drain amylase greater than three times the upper limit of the institutional normal serum amylase without an effect on clinical management or duration of hospital stay. BL will only be measured in those who had a peritoneal drain placed. Treatment arm differences will be assessed via logistic regression model with adjustment for stratification factor.

    Time frame: Up to 60 days after distal pancreatectomy

  2. Number of post-operation hospital days

    Mean hospital length of stay will be compared according to treatment arm via linear regression model with adjustment for stratification factor.

    Time frame: From the time of surgery up to 60 days after distal pancreatectomy

  3. Change in overall quality of life (QOL)

    Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Core 30 (C30). Treatment arm differences in EORTC QLQ-C30 changes will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures.

    Time frame: At baseline and at 14 and 60 days after surgery

Other outcomes

  1. Changes in pancreatic specific QOL

    Will be assessed using EORTC QLQ- Pancreatic Cancer 26. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures.

    Time frame: At baseline and up to 60 days after distal pancreatectomy

  2. Change in health-related QOL

    Will be assessed using the European Quality of Life Five Dimension Five Level scale. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures.

    Time frame: At baseline and up to 60 days after distal pancreatectomy

  3. Delayed gastric emptying (DGE)

    DGE will be defined by the ISGPS as reinsertion or persistence of a nasogastric tube after postoperative day (POD) 3 or inability to tolerate solid oral intake by POD 7. Treatment arm differences in the proportion of participants with DGE will be assessed via logistic regression model with adjustment for stratification factor.

    Time frame: Up to 60 days after distal pancreatectomy

  4. Incidence of grades B/C post-pancreatectomy hemorrhage (PPH)

    PPH will be defined by the ISGPS as postoperative intra- or extra-luminal hemorrhage requiring transfusion of fluid or blood, intensive care unit transfer, therapeutic endoscopy, endovascular embolization, or reoperation. Treatment arm differences in the proportion of participants with PPH will be assessed via logistic regression model with adjustment for stratification factor.

    Time frame: Up to 60 days after distal pancreatectomy

  5. Time to initiation of adjuvant chemotherapy

    Distributions of time from surgery to initiation of adjuvant chemotherapy, among participants with planned adjuvant chemotherapy, in each arm will be estimated via cumulative incidence and compared using the stratified log-rank test.

    Time frame: From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy

  6. Incidence of nausea and vomiting

    Proportions of participants with any nausea/vomiting will be compared between treatment arms via Fisher's exact test.

    Time frame: Up to 60 days after distal pancreatectomy

07

Study locations

18 of 118 sites recruiting
  • University of Alabama at Birmingham Cancer Center
    Birmingham, Alabama 35233, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
    Daphne, Alabama 36526, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Thomas Hospital
    Fairhope, Alabama 36532, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Mobile Infirmary Medical Center
    Mobile, Alabama 36607, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
    Saraland, Alabama 36571, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
    Suspended

    Not enrolling at this site — choose another above.

  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
    Suspended

    Not enrolling at this site — choose another above.

  • UC San Diego Moores Cancer Center
    La Jolla, California 92093, United States
    Recruiting
    • Site Public Contact · Contactcancercto@ucsd.edu · 858-822-5354
    • Andrew M. Lowy · Principal investigator
  • Veterans Affairs Loma Linda Healthcare System
    Loma Linda, California 92357, United States
    Suspended

    Not enrolling at this site — choose another above.

  • USC / Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    Suspended

    Not enrolling at this site — choose another above.

  • UC San Diego Medical Center - Hillcrest
    San Diego, California 92103, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Helen F Graham Cancer Center
    Newark, Delaware 19713, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Medical Oncology Hematology Consultants PA
    Newark, Delaware 19713, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Christiana Care Health System-Christiana Hospital
    Newark, Delaware 19718, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Christiana Care Health System-Wilmington Hospital
    Wilmington, Delaware 19801, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Moffitt Cancer Center at SouthShore
    Ruskin, Florida 33570, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Moffitt Cancer Center-International Plaza
    Tampa, Florida 33607, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Moffitt Cancer Center - McKinley Campus
    Tampa, Florida 33612, United States
    Recruiting
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Moffitt Cancer Center at Wesley Chapel
    Wesley Chapel, Florida 33544, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Grady Health System
    Atlanta, Georgia 30303, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Emory University Hospital Midtown
    Atlanta, Georgia 30308, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Emory University Hospital/Winship Cancer Institute
    Atlanta, Georgia 30322, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Emory Saint Joseph's Hospital
    Atlanta, Georgia 30342, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Emory Johns Creek Hospital
    Johns Creek, Georgia 30097, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Northwestern University
    Chicago, Illinois 60611, United States
    Recruiting
  • University of Illinois
    Chicago, Illinois 60612, United States
    Recruiting
    • Site Public Contact · Contact312-355-3046
    • Aslam Ejaz · Principal investigator
  • Northwestern Medicine Cancer Center Delnor
    Geneva, Illinois 60134, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Northwestern Medicine Oak Brook
    Oak Brook, Illinois 60523, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Northwestern Medicine Orland Park
    Orland Park, Illinois 60462, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Northwestern Medicine Cancer Center Warrenville
    Warrenville, Illinois 60555, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Indiana University/Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
    Suspended

    Not enrolling at this site — choose another above.

  • University of Kentucky/Markey Cancer Center
    Lexington, Kentucky 40536, United States
    Recruiting
    • Site Public Contact · Contact859-257-3379
    • Michael J. Cavnar · Principal investigator
  • University Medical Center New Orleans
    New Orleans, Louisiana 70112, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Christiana Care - Union Hospital
    Elkton, Maryland 21921, United States
    Suspended

    Not enrolling at this site — choose another above.

  • University of Michigan Rogel Cancer Center
    Ann Arbor, Michigan 48109, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Bronson Battle Creek
    Battle Creek, Michigan 49017, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
    Grand Rapids, Michigan 49503, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
    Grand Rapids, Michigan 49503, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Trinity Health Grand Rapids Hospital
    Grand Rapids, Michigan 49503, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Trinity Health Muskegon Hospital
    Muskegon, Michigan 49444, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Corewell Health Lakeland Hospitals - Niles Hospital
    Niles, Michigan 49120, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Cancer and Hematology Centers of Western Michigan - Norton Shores
    Norton Shores, Michigan 49444, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Corewell Health Reed City Hospital
    Reed City, Michigan 49677, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
    Saint Joseph, Michigan 49085, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
    Saint Joseph, Michigan 49085, United States
    Suspended

    Not enrolling at this site — choose another above.

  • University of Michigan Health - West
    Wyoming, Michigan 49519, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Riverwood Healthcare Center
    Aitkin, Minnesota 56431, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health - Baxter Clinic
    Baxter, Minnesota 56425, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health Saint Joseph's Medical Center
    Brainerd, Minnesota 56401, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health - Saint Joseph's Crosslake Clinic
    Crosslake, Minnesota 56442, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health - Deer River Clinic
    Deer River, Minnesota 56636, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health Saint Mary's - Detroit Lakes Clinic
    Detroit Lakes, Minnesota 56501, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health Cancer Center
    Duluth, Minnesota 55805, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health Saint Mary's Medical Center
    Duluth, Minnesota 55805, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Miller-Dwan Hospital
    Duluth, Minnesota 55805, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health - Ely Clinic
    Ely, Minnesota 55731, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health - Fosston
    Fosston, Minnesota 56542, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health Hibbing Clinic
    Hibbing, Minnesota 55746, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health - International Falls Clinic
    International Falls, Minnesota 56649, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health - Moose Lake Clinic
    Moose Lake, Minnesota 55767, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health - Park Rapids
    Park Rapids, Minnesota 56470, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health - Saint Joseph's Pequot Lakes Clinic
    Pequot Lakes, Minnesota 56472, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health - Saint Joseph's Pine River Clinic
    Pine River, Minnesota 56474, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health Sandstone
    Sandstone, Minnesota 55072, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health - Saint Joseph's Staples Clinic
    Staples, Minnesota 56479, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health Virginia Clinic
    Virginia, Minnesota 55792, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Parkland Health Center - Farmington
    Farmington, Missouri 63640, United States
    Recruiting
    • Site Public Contact · Contact314-996-5569
    • Bryan A. Faller · Principal investigator
  • Sainte Genevieve County Memorial Hospital
    Sainte Genevieve, Missouri 63670, United States
    Recruiting
    • Site Public Contact · Contact314-996-5569
    • Bryan A. Faller · Principal investigator
  • Missouri Baptist Medical Center
    St Louis, Missouri 63131, United States
    Recruiting
    • Site Public Contact · Contact314-996-5569
    • Bryan A. Faller · Principal investigator
  • Missouri Baptist Sullivan Hospital
    Sullivan, Missouri 63080, United States
    Recruiting
    • Site Public Contact · Contact314-996-5569
    • Bryan A. Faller · Principal investigator
  • BJC Outpatient Center at Sunset Hills
    Sunset Hills, Missouri 63127, United States
    Recruiting
    • Site Public Contact · Contact314-996-5569
    • Bryan A. Faller · Principal investigator
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Renown Regional Medical Center
    Reno, Nevada 89502, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Saint Barnabas Medical Center
    Livingston, New Jersey 07039, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
    Suspended

    Not enrolling at this site — choose another above.

  • University of New Mexico Cancer Center
    Albuquerque, New Mexico 87106, United States
    Suspended

    Not enrolling at this site — choose another above.

  • University of Rochester
    Rochester, New York 14642, United States
    Suspended

    Not enrolling at this site — choose another above.

  • State University of New York Upstate Medical University
    Syracuse, New York 13210, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Carolinas Medical Center/Levine Cancer Institute
    Charlotte, North Carolina 28203, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Atrium Health Cabarrus/LCI-Concord
    Concord, North Carolina 28025, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health Cancer Center-South University Clinic
    Fargo, North Dakota 58103, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Sanford Broadway Medical Center
    Fargo, North Dakota 58122, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Sanford Roger Maris Cancer Center
    Fargo, North Dakota 58122, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Essentia Health - Jamestown Clinic
    Jamestown, North Dakota 58401, United States
    Suspended

    Not enrolling at this site — choose another above.

  • University of Cincinnati Cancer Center-UC Medical Center
    Cincinnati, Ohio 45219, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
    Suspended

    Not enrolling at this site — choose another above.

  • University of Cincinnati Cancer Center-West Chester
    West Chester, Ohio 45069, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Saint Luke's Cancer Center - Allentown
    Allentown, Pennsylvania 18104, United States
    Recruiting
    • Site Public Contact · Contact610-776-4714
    • Darius C. Desai · Principal investigator
  • Saint Luke's University Hospital-Bethlehem Campus
    Bethlehem, Pennsylvania 18015, United States
    Recruiting
    • Site Public Contact · Contact484-503-4151
    • Darius C. Desai · Principal investigator
  • Christiana Care Health System-Concord Health Center
    Chadds Ford, Pennsylvania 19317, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Saint Luke's Hospital-Anderson Campus
    Easton, Pennsylvania 18045, United States
    Recruiting
    • Site Public Contact · Contactctsucontact@westat.com · 888-823-5923
    • Darius C. Desai · Principal investigator
  • Saint Luke's Hospital - Upper Bucks Campus
    Quakertown, Pennsylvania 18951, United States
    Recruiting
    • Site Public Contact · Contact610-776-4714
    • Darius C. Desai · Principal investigator
  • Saint Luke's Hospital - Monroe Campus
    Stroudsburg, Pennsylvania 18360, United States
    Recruiting
    • Site Public Contact · Contactctsucontact@westat.com · 888-823-5923
    • Darius C. Desai · Principal investigator
  • Geisinger Wyoming Valley/Henry Cancer Center
    Wilkes-Barre, Pennsylvania 18711, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Sanford Cancer Center Oncology Clinic
    Sioux Falls, South Dakota 57104, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Sanford USD Medical Center - Sioux Falls
    Sioux Falls, South Dakota 57117-5134, United States
    Suspended

    Not enrolling at this site — choose another above.

  • University of Tennessee - Knoxville
    Knoxville, Tennessee 37920, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Baptist Memorial Hospital and Cancer Center-Memphis
    Memphis, Tennessee 38120, United States
    Suspended

    Not enrolling at this site — choose another above.

  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
    Suspended

    Not enrolling at this site — choose another above.

Showing the first 100 of 118 sites. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Intara AS, Guthrie KA, Chauhan SSB, Arnold KB, Topacio R, Carvalho K, Garcia A, Fraser V, Wright GP, Sun V, Ahmad SA, Rocha FG, Chiorean EG, Philip P, Ecker BL, Reames BN, Karanicolas P, Krouse RS, Pillarisetty VG, Sham JG. Lanreotide for the prevention of postoperative pancreatic fistula (S2408): study protocol for a multicenter randomized controlled trial. Trials. 2026 Aug 3;27(1):634. doi: 10.1186/s13063-026-09933-8. PubMed 42958416 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Apr 2029, 46 months after the start.

Of 46 non-industry phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 79. This study's planned 46 months is below that.

Counting every sponsor, half of 84 studies reached it within 60 months; a quarter within 36 and three quarters within 77.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Nov 2027 → Apr 2029 and completion Nov 2027 → Apr 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Feb 4, 2025
StartActual
May 9, 2025
Primary completionEst.
Apr 1, 2029was Nov 2027
CompletionEst.
Apr 1, 2029was Nov 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 1, 2027→Apr 1, 2029
Nov 6, 2026
Study completion
Nov 1, 2027→Apr 1, 2029
Nov 6, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42958416 ↗
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42958416 ↗
    Primary completion Nov 1, 2027→Apr 1, 2029
    Study completion Nov 1, 2027→Apr 1, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06807437
Responsible party
Sponsor
First posted
Feb 4, 2025
Start date
May 9, 2025
Primary completion
Apr 1, 2029 (estimated)
Completion
Apr 1, 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Andrea Garcia
Contact
agarcia@swog.org
210-614-8808
Dana Sparks
Contact
dsparks@swog.org
210-614-8808
Jonathan G Sham
principal investigator · SWOG Cancer Research Network

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lanreotide

Start the discussion